Crinetics Pharmaceuticals, Inc.
DE ˙ DB ˙ US22663K1079
30,15 € ↓ -0,19 (-0,63%)
2026-06-01
CENA AKCJI
SecurityDE:6Z4 / Crinetics Pharmaceuticals, Inc.
InstitutionUBS Group AG
Latest Disclosed Ownership571,899 shares
Latest Disclosed Value $ 20,771,372
UBS Group AG ownership in 6Z4 / Crinetics Pharmaceuticals, Inc.

On May 5, 2026 - UBS Group AG filed a 13F-HR form disclosing ownership of 571,899 shares of Crinetics Pharmaceuticals, Inc. (DE:6Z4) valued at $16,928,210 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 29, 2026 disclosing 908,192 shares of Crinetics Pharmaceuticals, Inc.. This represents a change in shares of -37.03% during the quarter. The current value of the position is $17,242,755 USD.

UBS Group AG has a history of taking positions in derivatives of the underlying security (6Z4) in the form of stock options.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

DE:6Z4 / Crinetics Pharmaceuticals, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-05 2026-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 571,899 -336,293 -37.03 20,771 -50.87 0.0006
2026-01-29 2025-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 908,192 500,470 122.75 42,276 148.96 0.0012
2025-11-13 2025-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 407,722 87,177 27.20 16,982 84.22 0.0027
2025-08-14 2025-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 320,545 4,886 1.55 9,219 -12.93 0.0016
2025-05-13 2025-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 315,659 -392,071 -55.40 10,587 -70.74 0.0019
2025-02-14 2024-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 707,730 524,844 286.98 36,186 287.22 0.0067
2024-11-14 2024-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 182,886 -56 -0.03 9,345 14.06 0.0020
2024-08-14 2024-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 182,942 -64,861 -26.17 8,194 -29.36 0.0020
2024-05-13 2024-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 247,803 109,338 78.96 11,600 135.46 0.0029
2024-02-09 2023-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 138,465 56,607 69.15 4,927 102.38 0.0015
2023-11-09 2023-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 81,858 -63,835 -43.81 2,434 -7.28 0.0008
2023-08-11 2023-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 145,693 86,525 146.24 2,625 176.32 0.0009
2023-05-12 2023-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 59,168 -21,526 -26.68 950 -35.64 0.0003
2023-02-08 2022-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 80,694 72,555 891.45 1,477 822.50 0.0006
2022-11-10 2022-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 8,139 -11,041 -57.57 160 -55.31 0.0001
2022-08-10 2022-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 19,180 -49,313 -72.00 358 -76.20 0.0001
2022-05-16 2022-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 68,493 15,673 29.67 1,504 0.27 0.0005
2022-02-14 2021-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 52,820 31,593 148.83 1,500 235.57 0.0004
2021-11-15 2021-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 21,227 21,227 447 0.0001
2021-08-13 2021-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 0 -4,129 -100.00 0 -100.00
2021-05-12 2021-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 4,129 2,030 96.71 63 110.00 0.0000
2021-02-11 2020-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 2,099 2,099 30 0.0000
2020-11-12 2020-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 0 -9,093 -100.00 0 -100.00
2020-07-31 2020-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 9,093 877 10.67 159 31.40 0.0001
2020-05-01 2020-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 8,216 -8,871 -51.92 121 -71.79 0.0001
2020-02-14 2019-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 17,087 7,888 85.75 429 210.87 0.0001
2019-11-14 2019-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 9,199 8,514 1,242.92 138 711.76 0.0001
2019-08-14 2019-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 685 -42,731 -98.42 17 -98.28 0.0000
2019-05-14 2019-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 43,416 42,821 7,196.81 988 5,388.89 0.0004
2019-02-14 2018-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 595 -1,042 -63.65 18 -61.70 0.0000
2018-11-14 2018-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 1,637 1,637 47 0.0000
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2024-08-14 2024-06-30 13F CRINETICS PHARMACEUTICALS IN COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2024-05-13 2024-03-31 13F CRINETICS PHARMACEUTICALS IN COM Put 20,000 936 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.